Cell Cycle Arrest, Cytotoxicity, Apoptosis, DNA‐Binding, Photocleavage, and Antioxidant Activity of Octahedral Ruthenium(II) Complexes

Huang, Hongliang; Li, Zhengzheng; Liang, Zhen-Hua; Liu, Yun-Jun

doi:10.1002/ejic.201100848

Cited by 50 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of two bromine atoms can enhance the cytoxicity activity of compound 2. Compared 2 with cisplatin (Huang et al, 2011;Cheng et al, 2009), compound 2 showed high cytotoxicity against BEL-7402, Hela, and SKBR-3 cells. The differences in cytotoxicity of compounds 1-4 may be caused by a different log P value.…”

Section: Discussionmentioning

confidence: 98%

Cytotoxicity, Cell Cycle Arrest, Antioxidant Activity and Interaction of Dibenzoxanthenes Derivatives with DNA

Wang

Yang

Lin

et al. 2012

DNA and Cell Biology

View full text Add to dashboard Cite

In this study, we report the DNA interaction and cytotoxicity of four dibenzoxanthene compounds 1-4. The binding behaviors of these compounds to calf thymus DNA were studied by absorption titration, viscosity measurements. The DNA binding constants of compounds 1, 2, 3, and 4 are 5.05×10(4), 2.13×10(3), 5.10×10(4), and 3.03×10(3) M(-1), respectively. The lipophilicity of the compounds was determined by the shake flask method. The cytotoxicity of these compounds has been assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. These compounds exhibit high activity against BEL-7402, Hela, MG-63, and SKBR-3 cells. The cell cycle arrest was analyzed by flow cytometry. These compounds inhibit S phase of BEL-7402 and SKBR-3 cells. The experiments on antioxidant activity show that these compounds exhibit good antioxidant activity against hydroxyl radical ((•)OH).

show abstract

Section: Discussionmentioning

confidence: 98%

Cytotoxicity, Cell Cycle Arrest, Antioxidant Activity and Interaction of Dibenzoxanthenes Derivatives with DNA

Wang

Yang

Lin

et al. 2012

DNA and Cell Biology

View full text Add to dashboard Cite

show abstract

“…Ruthenium complexes with pyridyl-based ligands are of special interest due to a combination of easily constructed rigid chiral structures and useful photophysical properties. The large, rigid, and multidentate polypyridyl ligands confer shape and chirality to the ruthenium complexes that could be utilized to achieve customized DNA binding properties [88][89][90]. Following the literature reports on the pharmacological benefits of attaching carboxylic acid (COOH) group in coordination complexes [91] Figure 20) [92].…”

Section: Inorganic Ruthenium(ii)mentioning

confidence: 99%

Anticancer Activities of Mononuclear Ruthenium(II) Coordination Complexes

Motswainyana

Ajibade

2015

Advances in Chemistry

View full text Add to dashboard Cite

Ruthenium compounds are highly regarded as potential drug candidates. The compounds offer the potential of reduced toxicity and can be tolerated in vivo. The various oxidation states, different mechanism of action, and the ligand substitution kinetics of ruthenium compounds give them advantages over platinum-based complexes, thereby making them suitable for use in biological applications. Several studies have focused attention on the interaction between active ruthenium complexes and their possible biological targets. In this paper, we review several ruthenium compounds which reportedly possess promising cytotoxic profiles: from the discovery of highly active compounds imidazolium [trans-tetrachloro(dmso)(imidazole)ruthenate(III)] (NAMI-A), indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)](KP1019), and sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) to the recent work based on both inorganic and organometallic ruthenium(II) compounds. Half-sandwich organometallic ruthenium complexes offer the opportunity of derivatization at the arene moiety, while the three remaining coordination sites on the metal centre can be functionalised with various coordination groups of various monoligands. It is clear from the review that these mononuclear ruthenium(II) compounds represent a strongly emerging field of research that will soon culminate into several ruthenium based antitumor agents.

show abstract

“…The compound NAMI-A, ImH[ trans -RuCl 4 (DMSO)Im] (Im = imidazole), has shown very promising properties in preclinical and phase I clinical trials against lung metastases (Bergamo et al 1999; Morbidelli et al 2003; Rademaker-Lakhai et al 2004; Sava et al 2002; Sava et al 1998) while KP1019, IndH[ trans -RuCl 4 (Ind) 2 ] (Ind = indazole), is effective in ovarian and colon carcinomas (Berger et al 1989; Bratsos et al 2007b; Garzon et al 1987; Hartinger et al 2008; Jakupec et al 2008; Kapitza et al 2005; Seelig et al 1992). In addition, three octahedral Ru (II) complexes were found to induce apoptosis when tested on human hepatoma (BEL-7402 and HepG-2), ovarian (HeLa), and osteosarcoma (MG-63) cancer cell lines (Huang et al, 2011). Most recently, two symmetric ruthenium(II) complexes were found to exert apoptosis on the BEL-7402, HeLa, MG-63 and SKBR (breast) cancer cell lines (Xie et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Analysis of the cytotoxic effects of ruthenium–ketoconazole and ruthenium–clotrimazole complexes on cancer cells

et al. 2013

View full text Add to dashboard Cite

Ruthenium-based compounds have intriguing anti-cancer properties and some of these novel compounds are currently in clinical trials. To continue the development of new metal-based drug combinations, we coupled ruthenium (Ru) with the azole compounds ketoconazole (KTZ) and clotrimazole (CTZ), which are well-known antifungal agents that also display anticancer properties. We report the activity of a series of twelve Ru-KTZ and Ru-CTZ compounds against three prostate tumor cell lines with different androgen sensitivity, as well as cervical cancer and lymphoblastic lymphoma cell lines. In addition, human cell lines were used to evaluate the toxicity against non-transformed cells and to establish selectivity indexes. Our results indicate that the combination of ruthenium and KTZ/CTZ in a single molecule results in complexes that are more cytotoxic than the individual components alone, displaying in some cases low micromolar CC50 values and high selectivity indexes. Additionally, all compounds are more cytotoxic against prostate cell lines with lower cytotoxicity against non-transformed epidermal cell lines. Some of the compounds were found to primarily induce cell death via apoptosis yet weakly interact with DNA. Our studies also demonstrate that the cytotoxicity induced by our Ru-based compounds is not directly related to their ability to interact with DNA.

show abstract

Cell Cycle Arrest, Cytotoxicity, Apoptosis, DNA‐Binding, Photocleavage, and Antioxidant Activity of Octahedral Ruthenium(II) Complexes

Cited by 50 publications

References 43 publications

Cytotoxicity, Cell Cycle Arrest, Antioxidant Activity and Interaction of Dibenzoxanthenes Derivatives with DNA

Cytotoxicity, Cell Cycle Arrest, Antioxidant Activity and Interaction of Dibenzoxanthenes Derivatives with DNA

Anticancer Activities of Mononuclear Ruthenium(II) Coordination Complexes

Analysis of the cytotoxic effects of ruthenium–ketoconazole and ruthenium–clotrimazole complexes on cancer cells

Contact Info

Product

Resources

About